Pharmaxis closes IPO oversubscribed
Wednesday, 29 October, 2003
Sydney-based Pharmaxis closed its IPO yesterday, three days earlier than scheduled after strong demand from investors.
As a result of the early closing of the IPO, the scheduled listing date for Pharmaxis has been brought forward to November 10.
The offering, which was originally planned to raise $21 million at a price of AUD$0.50 per ordinary share, was oversubscribed by 8 million shares, raising an extra $4 million for the company.
"Demand for share ownership in Pharmaxis has been very strong, from both new retail and institutional investors, as well as our existing base of shareholders," said CEO Alan Robertson.
"The successful completion of this IPO means we are now well positioned to rapidly progress the development and commercialisation of the company's clinical projects, as well as the scale-up of our manufacturing capability."
The company, which specialises in human therapeutic products for chronic respiratory and autoimmune diseases, has four products in clinical trials and two in pre-clinical development.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
